161 related articles for article (PubMed ID: 34283061)
1. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis.
Koch EAT; Petzold A; Wessely A; Dippel E; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Hohberger B; Kähler KC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schell B; Schlaak M; Terheyden P; Thoms KM; Schuler-Thurner B; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV; On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283061
[TBL] [Abstract][Full Text] [Related]
2. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.
Koch EAT; Petzold A; Wessely A; Dippel E; Eckstein M; Gesierich A; Gutzmer R; Hassel JC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schlaak M; Thoms KM; Ugurel S; Utikal J; Weichenthal M; Schuler-Thurner B; Berking C; Heppt MV
Front Med; 2023 Oct; 17(5):878-888. PubMed ID: 37432641
[TBL] [Abstract][Full Text] [Related]
3. Clinical determinants of long-term survival in metastatic uveal melanoma.
Koch EAT; Petzold A; Wessely A; Dippel E; Erdmann M; Heinzerling L; Hohberger B; Knorr H; Leiter U; Meier F; Mohr P; Rahimi F; Schell B; Schlaak M; Terheyden P; Schuler-Thurner B; Ugurel S; Utikal J; Vera J; Weichenthal M; Ziller F; Berking C; Heppt MV
Cancer Immunol Immunother; 2022 Jun; 71(6):1467-1477. PubMed ID: 34709438
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity.
Koch EAT; Petzold A; Wessely A; Dippel E; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schell B; Schlaak M; Terheyden P; Thoms KM; Schuler-Thurner B; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158786
[TBL] [Abstract][Full Text] [Related]
5. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
Koch EAT; Petzold A; Dippel E; Erdmann M; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schell B; Terheyden P; Thoms KM; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
Front Immunol; 2024; 15():1395225. PubMed ID: 38915414
[TBL] [Abstract][Full Text] [Related]
6. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
7. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
8. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators.
Byun HK; Chang JS; Jung M; Koom WS; Chung KY; Oh BH; Roh MR; Kim KH; Lee CK; Shin SJ
Front Oncol; 2021; 11():659754. PubMed ID: 34123816
[TBL] [Abstract][Full Text] [Related]
11. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
Heppt MV; Steeb T; Schlager JG; Rosumeck S; Dressler C; Ruzicka T; Nast A; Berking C
Cancer Treat Rev; 2017 Nov; 60():44-52. PubMed ID: 28881222
[TBL] [Abstract][Full Text] [Related]
14. The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
Tosi A; Cappellesso R; Dei Tos AP; Rossi V; Aliberti C; Pigozzo J; Fabozzi A; Sbaraglia M; Blandamura S; Del Bianco P; Chiarion-Sileni V; Rosato A
J Exp Clin Cancer Res; 2021 May; 40(1):154. PubMed ID: 33947438
[TBL] [Abstract][Full Text] [Related]
15. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.
Gonsalves CF; Eschelman DJ; Sullivan KL; Anne PR; Doyle L; Sato T
AJR Am J Roentgenol; 2011 Feb; 196(2):468-73. PubMed ID: 21257902
[TBL] [Abstract][Full Text] [Related]
16. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma.
Placke JM; Soun C; Bottek J; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Pfeiffer C; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Zimmer L; Livingstone E; Becker JC; Lodde G; Sucker A; Griewank K; Horn S; Hadaschik E; Roesch A; Schadendorf D; Engel DR; Ugurel S
Front Oncol; 2021; 11():741993. PubMed ID: 34621681
[TBL] [Abstract][Full Text] [Related]
17. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
18. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
[TBL] [Abstract][Full Text] [Related]
19. Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer.
Lu Z; Zou J; Hu Y; Li S; Zhou T; Gong J; Li J; Zhang X; Zhou J; Lu M; Wang X; Peng Z; Qi C; Li Y; Li J; Li Y; Zou J; Du X; Zhang H; Shen L
JAMA Netw Open; 2019 Jul; 2(7):e197621. PubMed ID: 31339548
[TBL] [Abstract][Full Text] [Related]
20. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
Bolte LA; Lee KA; Björk JR; Leeming ER; Campmans-Kuijpers MJE; de Haan JJ; Vila AV; Maltez-Thomas A; Segata N; Board R; Harries M; Lorigan P; de Vries EGE; Nathan P; Fehrmann R; Bataille V; Spector TD; Hospers GAP; Weersma RK
JAMA Oncol; 2023 May; 9(5):705-709. PubMed ID: 36795408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
